What's in Placebos: Who Knows? Analysis of Randomized, Controlled Trials

被引:49
作者
Golomb, Beatrice A.
Erickson, Laura C.
Koperski, Sabrina
Sack, Deanna
Enkin, Murray
Howick, Jeremy
机构
[1] Univ Calif San Diego, Sch Med, San Diego, CA 92103 USA
[2] McMaster Univ, Hamilton, ON, Canada
[3] Univ Oxford, Ctr Evidence Based Med, Oxford, England
基金
英国医学研究理事会;
关键词
LACTOSE-INTOLERANCE; HEART-DISEASE; OLIVE OIL; COUGH;
D O I
10.7326/0003-4819-153-8-201010190-00010
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: No regulations govern placebo composition. The composition of placebos can influence trial outcomes and merits reporting. Purpose: To assess how often investigators specify the composition of placebos in randomized, placebo-controlled trials. Data Sources: 4 English-language general and internal medicine journals with high impact factors. Study Selection: 3 reviewers screened titles and abstracts of the journals to identify randomized, placebo-controlled trials published from January 2008 to December 2009. Data Extraction: Reviewers independently abstracted data from the introduction and methods sections of identified articles, recording treatment type (pill, injection, or other) and whether placebo composition was stated. Discrepancies were resolved by consensus. Data Synthesis: Most studies did not disclose the composition of the study placebo. Disclosure was less common for pills than for injections and other treatments (8.2% vs. 26.7%; P = 0.002). Limitation: Journals with high impact factors may not be representative. Conclusion: Placebos were seldom described in randomized, controlled trials of pills or capsules. Because the nature of the placebo can influence trial outcomes, placebo formulation should be disclosed in reports of placebo-controlled trials.
引用
收藏
页码:532 / 535
页数:4
相关论文
共 21 条
[1]   CONTROLLED TRIAL OF CLOFIBRATE IN CEREBRAL VASCULAR-DISEASE [J].
ACHESON, J ;
HUTCHINSON, EC .
ATHEROSCLEROSIS, 1972, 15 (02) :177-+
[2]  
[Anonymous], 1971, Br Med J, V4, P775
[3]   Bioactive effects of olive oil phenolic compounds in humans: Reduction of heart disease factors and oxidative damage [J].
Covas M.-I. .
Inflammopharmacology, 2008, 16 (5) :216-218
[4]  
Cullinen Kathleen, 2006, Med Health R I, V89, P113
[5]  
DEAN AG, 2009, OPENEPI OPEN SOURCE, V2010
[6]   Mechanisms of the placebo effect of sweet cough syrups [J].
Eccles, Ronald .
RESPIRATORY PHYSIOLOGY & NEUROBIOLOGY, 2006, 152 (03) :340-348
[7]   Antioxidant effect of virgin olive oil in patients with stable coronary heart disease:: a randomized, crossover, controlled, clinical trial [J].
Fitó, M ;
Cladellasc, M ;
de la Torre, R ;
Martí, J ;
Alcántara, M ;
Pujadas-Bastardes, M ;
Marrugat, J ;
Bruguera, J ;
López-Sabater, MC ;
Vila, J ;
Covas, MI .
ATHEROSCLEROSIS, 2005, 181 (01) :149-158
[8]  
Golomb B, 2002, JAMA-J AM MED ASSOC, V287, P2502
[9]   PARADOX OF PLACEBO-EFFECT [J].
GOLOMB, BA .
NATURE, 1995, 375 (6532) :530-530
[10]   Doctoring the Evidence: The Case Against Lying to Patients about Placebos [J].
Golomb, Beatrice A. .
AMERICAN JOURNAL OF BIOETHICS, 2009, 9 (12) :34-36